Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EC Healthcare
醫思健康
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2138)

INSIDE INFORMATION
POSITIVE PROFIT ALERT

This announcement is made by EC Healthcare (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

The board of directors (the "**Directors**") of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the latest assessment by the Board with reference to the preliminary unaudited consolidated management accounts of the Group for the six months ended 30 September 2026 (the "**Reporting Period**") currently available the Group is expected to record:

(i) a turnaround from loss to profit attributable to equity shareholders of the Company ("**Attributable Net Profit**") of not less than HK$3.0 million for the Reporting Period, as compared with a loss attributable to equity shareholders of approximately HK$10.3 million for the corresponding period ended 30 September 2025; and

(ii) an increase of not less than 250% in net profit after tax ("**Net Profit**") for the Reporting Period, as compared with the net profit of approximately HK$4.2 million for the corresponding period ended 30 September 2025.

The expected improvement in the Group's Net Profit for the Reporting Period was primarily attributable to the following factors:

(i) reduction in depreciation and amortisation expenses, reflecting the Group's ongoing optimisation of its operating infrastructure, rationalisation of its asset base and disciplined capital allocation; and

(ii) decrease in finance costs, reflecting the Group's prudent treasury management and continued efforts to optimise its capital structure and financing efficiency.

The above favourable factors are expected to offset the decline in the Group's earnings before interest, tax, depreciation and amortisation ("**EBITDA**") during the Reporting Period as compared with the corresponding period ended 30 September 2025.

The Board is of the view that the Group's overall financial position remains stable, with cash and cash equivalents, time deposits, and other readily realisable financial assets expected to be not less than HK$900.0 million during the Reporting Period.

The Board wishes to remind Shareholders and potential investors that the Company is still in the process of finalising the interim results of the Group for the six months ended 30 September 2026. The financial information disclosed in this announcement is based on the preliminary unaudited consolidated management accounts of the Group and information currently available to the Board, which have not yet been finalised nor reviewed by the Company's auditors and may be subject to adjustments.

Shareholders and potential investors are advised to read carefully the interim results announcement of the Company, which is expected to be published on 27 November 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EC Healthcare
Raymond Siu
Company Secretary

Hong Kong, 23 November 2026

As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie and Mr. Lee Heung Wing; the non-executive Directors are Mr. Luk Kun Shing Ben and Mrs. Leung Yang, Shih Ti Marianne; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Au Tsun.